These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38898003)

  • 1. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies.
    Yu P; Zhu C; You X; Gu W; Wang X; Wang Y; Bu R; Wang K
    Cell Death Dis; 2024 Jun; 15(6):433. PubMed ID: 38898003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.
    Salifu I; Singh N; Berraondo M; Remon J; Salifu S; Severson E; Quintana A; Peiró S; Ramkissoon S; Vidal L; Chico I; Saini KS
    Cancer Treat Res Commun; 2023; 36():100713. PubMed ID: 37172552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.
    Saini KS; Punie K; Twelves C; Bortini S; de Azambuja E; Anderson S; Criscitiello C; Awada A; Loi S
    Expert Opin Biol Ther; 2021 Jul; 21(7):945-962. PubMed ID: 34043927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving treatment landscape of advanced urothelial carcinoma.
    Andreev-Drakhlin AY; Egoryan G; Shah AY; Msaouel P; Alhalabi O; Gao J
    Curr Opin Oncol; 2021 May; 33(3):221-230. PubMed ID: 33818541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Kim JH; Chang IH
    Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.
    Zhu N; Weng S; Wang J; Chen J; Yu L; Fang X; Yuan Y
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3021-3036. PubMed ID: 31617075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.
    Nathan P; Rajeh A; Noor M; Boldt G; Fernandes R
    Curr Oncol; 2024 Apr; 31(4):2316-2327. PubMed ID: 38668075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates in Uro-Oncology.
    Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
    Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy.
    You X; Zhu C; Yu P; Wang X; Wang Y; Wang J; Yu J; Wang K
    Biomed Pharmacother; 2024 Feb; 171():116152. PubMed ID: 38228034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
    Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():1956. PubMed ID: 32983126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors in genitourinary malignancies.
    Thana M; Wood L
    Curr Oncol; 2020 Apr; 27(Suppl 2):S69-S77. PubMed ID: 32368176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
    Hasan MM; Laws M; Jin P; Rahman KM
    Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating Prostate Cancer by Antibody-Drug Conjugates.
    Rosellini M; Santoni M; Mollica V; Rizzo A; Cimadamore A; Scarpelli M; Storti N; Battelli N; Montironi R; Massari F
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.